OZURDEX
® intravitreal implant has been proven effective for noninfectious posterior segment uveitis
in a clinical trial. OZURDEX
® helps treat the inflammation causing vitreous haze
that is affecting your vision. Your doctor will discuss more specific
reasons why he or she selected OZURDEX
® as well as the benefits and
risks of treatment.
What the study showed
OZURDEX® has been evaluated in a clinical
trial and approved by the FDA. The effectiveness and safety of OZURDEX®
intravitreal implants have been studied in 153 patients who had noninfectious uveitis
affecting the posterior segment of the eye.
OZURDEX® reduced vitreous haze and provided 3-line gains of vision on the eye chart for many patients vs sham
In a clinical study:
- 46.8% of OZURDEX® patients (about 47 of 100) achieved a vitreous haze score of zero, that is, no detectable haze, at week 8—compared with 11.8% of patients (about 12 of 100) who received sham (simulated) injections
- Also at week 8, 42.9% of OZURDEX® patients (about 43 of 100) had gained 3 or more
lines of vision on the eye chart compared with 6.6% of patients (about 7 of 100) who received sham injections
It's important to remember that each case of uveitis is unique. Your own results
may vary.
Click the buttons below to learn more about OZURDEX® and how it works:
